KaydedilenlerDerginizi ekleyin

Dergiler / International Journal of Chemistry and Technology / 2019 / Volume: 3 Issue: 2

Inhibition effects of commonly used some antibacterial and antiviral drugs on purified human serum paraoxonase-1 (hPON1)

Hakan Soyut0000-0002-0361-7458
Sayfa
—
Yayın Tarihi
2019-12-31
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

IC50 values were determined.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:hPON1 is an enzyme from the group of A-esterases which is capable of hydrolyzing the active metabolite paraoxon of parathion, an organic phosphorus insecticide.
📊
Temel Bulgular & Veri:In this study, human serum PON1 was purified using three simple biochemical purification techniques.
💡
Sonuç & Katkı:IC50 values were determined.
🔬Tür:Research Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Paraoxonase · enzyme inhibition · antibacterial drug

Abstract

hPON1 is an enzyme from the group of A-esterases which is capable of hydrolyzing the active metabolite paraoxon of parathion, an organic phosphorus insecticide. It is an important liver enzyme that plays a protective role against the hydrolysis of HDL-induced organophosphate agents and nerve gases, oxidation of LDL, formation of lipid peroxides and bacterial endotoxins. The fact that oxidation of LDL constitutes the initial stage of the atherosclerosis process reveals the importance of the antioxidant properties of the enzyme. In this study, human serum PON1 was purified using three simple biochemical purification techniques. Furthermore, the in vitro effects of some antibacterial and antiviral drugs on human serum PON1 enzyme activity were examined. IC50 values were determined.

🔖

Bu Makaleye Atıf Yap

Soyut, H. (2019). Inhibition effects of commonly used some antibacterial and antiviral drugs on purified human serum paraoxonase-1 (hPON1). International Journal of Chemistry and Technology, Volume: 3 Issue: 2. https://doi.org/10.32571/ijct.651334

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Bandettini di Poggio, M.; Anfosso, S.; Audenino, D.; Primavera, A. J. Clin. Neurosci. 2011, 18, 313-318.
  2. Giamarellos-Bourboulis, E.J.; Antonopoulou, A.; Raftogiannis, M. Koutoukas P, Tsaganos, T., Tziortzioti, V., Panagou, C., Adamis, T., Giamarellou, H. BMC Infect. Dis. 2006, 21, 31.
  3. Cheathama, S. C.; Shea, K. M.; Healy, D. P.; Humphrey, M. L.; Fleming, M. R.; Wack, M. F.; Smith, D. W.; Sowinski, K. M.; Kays, M. B. Int. J. Antimicrob. AG. 2011, 37 (1), 46-50.
  4. Singh, A. K.; Quraishi, M. A. Corros. Sci. 2010, 52, 152-160.
  5. Khersonsky, O.; Tawfik, D. S. Biochemistry 2005, 44, 6371-6382.
  6. Türkeş, C.; Söyüt, H.; Beydemir, Ş. Pharmacol. Rep. 2014, 66, 74-78.
  7. Türkeş, C.; Söyüt, H.; Beydemir, Ş. J. Enzyme Inhib. Med. Ch. 2015, 30, 622–628.
  8. Türkeş, C.; Söyüt, H.; Beydemir, Ş. Environ. Toxicol. Phar. 2016, 42, 252-257.
  9. Gaidukov, L.; Tawfik, D. S. Biochemistry 2005, 44, 11843-11854.
  10. Renault, F.; Chabriere, E.; Andrieu, J.P.; Dublet, B.; Massona, P.; Rochua, D. J. Chromatogyr. B, 2006, 836, 15-21.
  11. Aviram, M.; Rosenblat, M. Free Radical Bio. Med. 2004, 37, 1304–1316.
  12. Rozenberg, O.; Shih, S. D.; Aviram, M. Atherosclerosis 2005, 181, 9–18.
  13. Ekinci, D.; Beydemir, S. J. Enzyme Inhib. Med. Ch. 2009, 24, 1034-1039.
  14. Ekinci, D.; Beydemir, S. Eur. J. Pharmacol. 2009, 617, 84-89.
  15. Giamarellos-Bourboulis, E.J.; Antonopoulou, A.; Raftogiannis, M. Koutoukas P, Tsaganos, T., Tziortzioti, V., Panagou, C., Adamis, T., Giamarellou, H. BMC Infect. Dis. 2006, 21, 31.